New drug combo targets rare and aggressive brain cancer
NCT ID NCT07405255
Summary
This study is testing whether adding the drug zanubrutinib to standard chemotherapy helps control a rare and aggressive type of brain cancer called primary central nervous system lymphoma. It will enroll 19 newly diagnosed patients in China to see if this combination leads to complete remission and improves survival. The trial is in Phase 2, meaning researchers are assessing how well it works and monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Conditions
Explore the condition pages connected to this study.